Hologic's 2024 Sustainability Report, covering fiscal year October 1, 2023, to September 28, 2024, highlighted significant operational achievements including FDA clearance for the Genius Digital Diagnostics System for cytology. The company also launched Genius A 2.0 technology for breast cancer detection.
The report detailed strategic acquisitions of Endomagnetics and Gynesonics, expanding Hologic's portfolio in breast cancer surgery and fibroid treatment. The company also noted over 3,300 Panther molecular diagnostic systems installed worldwide and the unveiling of the next-generation Envision mammography platform in December 2024.
Hologic reaffirmed its commitment to environmental, social, and governance (ESG) principles, aligning environmental targets with the Science Based Targets initiative (SBTi) and establishing Net Zero emission ambitions by 2050. The company also maintained a gender zero net pay gap and reported 42% women in its global workforce.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.